id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-E-0218-0009,FDA,FDA-2013-E-0218,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2018-03-21T04:00:00Z,2018,3,2018-03-21T04:00:00Z,,2018-03-21T12:44:54Z,,0,0,0900006483035fae
FDA-2013-E-0218-0008,FDA,FDA-2013-E-0218,"Determination of Regulatory Review Period for Purposes of Patent
Extension; RECUVYRA; Affirmation",Notice,Determinations,2017-08-23T04:00:00Z,2017,8,2017-08-23T04:00:00Z,,2017-08-23T14:13:16Z,2017-17961,0,0,0900006482a9e2ef
FDA-2013-E-0218-0006,FDA,FDA-2013-E-0218,Determination of Regulatory Review Period for Purposes of Patent Extension; RECUVYRA,Notice,Determinations,2017-08-21T04:00:00Z,2017,8,2017-08-21T04:00:00Z,2018-02-21T04:59:59Z,2017-08-22T01:05:23Z,2017-17566,0,0,0900006482a8cdde
FDA-2013-E-0218-0005,FDA,FDA-2013-E-0218,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-06-06T04:00:00Z,2017,6,2017-06-06T04:00:00Z,,2017-06-06T14:15:08Z,,0,0,09000064826971f8
FDA-2013-E-0218-0004,FDA,FDA-2013-E-0218,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2016-12-28T05:00:00Z,2016,12,2016-12-28T05:00:00Z,,2016-12-28T12:48:16Z,,0,0,0900006482439154
FDA-2013-E-0218-0003,FDA,FDA-2013-E-0218,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-05-02T04:00:00Z,2016,5,2016-05-02T04:00:00Z,,2016-05-02T23:15:20Z,,0,0,0900006481fa1d46
FDA-2013-E-0218-0001,FDA,FDA-2013-E-0218,Eli Lilly and Company - Patent Extension Application,Other,Application,2013-02-22T05:00:00Z,2013,2,2013-02-22T05:00:00Z,,2013-03-08T14:43:54Z,,0,0,0900006481203bc0
FDA-2013-E-0218-0002,FDA,FDA-2013-E-0218,U.S. Patent and Trademark Office - Letter,Other,Letter(s),2013-02-22T05:00:00Z,2013,2,2013-02-22T05:00:00Z,,2013-02-22T19:05:36Z,,0,0,0900006481203be1